Weekly Recap | Scribe Therapeutics +64.64%, most brokers rate it buy

The Week

Scribe Therapeutics (SCTX) closed the week at $34.13, surging +64.64% while the S&P 500 shed -1.43%, leaving the stock outperforming the benchmark by roughly 66 percentage points. It was a one-way rally from the start. Monday opened soft near $20.58 and dipped to an intraweek low of $19.875 before steadying. Tuesday brought a volume explosion and a ~27% gain, followed by another powerful leg higher on Wednesday and Thursday. By Thursday’s session the stock had tagged a fresh 52-week high of $39.60. Friday saw some consolidation between $33.90 and $36.89, with the week ending at $34.13. The weekly swing reached 95.85%, and average daily turnover more than doubled the prior median — a week of exceptionally heavy trading.

Key Events

This week’s firepower came from a wave of analyst initiations that reset the market’s attention on Scribe. The move kicked off after Tuesday’s close when multiple brokers launched coverage. By Wednesday, the stock had printed a new 52-week high on Nasdaq, with media reports pointing directly to the analyst upgrades. On Thursday, SCTX rallied more than 15% intraday and later stretched gains past 24%, landing on the day’s list of notable movers alongside names like Deere and Coinbase. Heading into Friday, the pre-market tape showed SCTX up over 11%, placing it among the session’s top-traded stocks. Biotech stocks broadly featured in the 52-week-high column that day, and SCTX stood out within the group. The narrative of the week was simple: analyst coverage arrived, and the market rapidly repriced a gene-editing name that had previously flown under the radar.

Analyst Ratings

Four brokers published ratings on Scribe Therapeutics this week: three came in at buy and one at no opinion, with no hold, underweight, or sell ratings on the board. The consensus recommendation stands at strong buy, and the consensus target price is $49, which implies a ~43.6% upside from the week’s close of $34.13. The target range spans $37 to $60, a wide spread that signals a fair degree of disagreement about the company’s long-term value. Within the biotechnology sector, SCTX ranks 327th out of 505 peers — a middle-of-the-pack position among rated companies.

The Week Ahead

The macro calendar takes centre stage next week. Tuesday, 25 August, brings a flurry of US housing and consumer data: FHFA house prices, the Case Shiller 20-city index, new home sales, and the consumer confidence reading. The consumer confidence figure is expected to edge down to 90.1 from 90.8, and a downside surprise could rattle broader risk appetite. For SCTX, having just been repriced so aggressively, the absence of fresh company-specific catalysts means the stock’s near-term direction will likely hinge on macro sentiment and sector rotation patterns.

In Short

SCTX delivered a textbook analyst-driven re-rating this week. The strong buy consensus and a target price well above spot create clear upward tension, yet the wide target range and a middling sector rank suggest the market is far from aligned on the story of a pre-revenue gene-editing firm. The latest session’s post-market flow showed small and medium orders tilting net seller while large-lot money stayed neutral, hinting at some profit-taking appetite. Holding current levels will require new validation — whether from the pipeline or commercial progress. In the meantime, macro data and biotech sentiment are likely to drive the next swing.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.